Generic Injectables Industry Research Report 2023

Generic Injectables Industry Research Report 2023


Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

Highlights

The global Generic Injectables market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Generic Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Injectables.
The Generic Injectables market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Generic Injectables market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC

Product Type Insights

Global markets are presented by Generic Injectables type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Generic Injectables are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Generic Injectables segment by Type
Small Molecule
Large Molecule

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Generic Injectables market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Generic Injectables market.
Generic Injectables Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Generic Injectables market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Generic Injectables industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Generic Injectables by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Small Molecule
1.2.3 Large Molecule
2.3 Generic Injectables by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Oncology
2.3.3 Anesthesia
2.3.4 Anti-Infectives
2.3.5 Parenteral Nutrition
2.3.6 Cardiovascular Diseases
2.4 Assumptions and Limitations
3 Generic Injectables Breakdown Data by Type
3.1 Global Generic Injectables Historic Market Size by Type (2018-2023)
3.2 Global Generic Injectables Forecasted Market Size by Type (2023-2028)
4 Generic Injectables Breakdown Data by Application
4.1 Global Generic Injectables Historic Market Size by Application (2018-2023)
4.2 Global Generic Injectables Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Generic Injectables Market Perspective (2018-2029)
5.2 Global Generic Injectables Growth Trends by Region
5.2.1 Global Generic Injectables Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Generic Injectables Historic Market Size by Region (2018-2023)
5.2.3 Generic Injectables Forecasted Market Size by Region (2024-2029)
5.3 Generic Injectables Market Dynamics
5.3.1 Generic Injectables Industry Trends
5.3.2 Generic Injectables Market Drivers
5.3.3 Generic Injectables Market Challenges
5.3.4 Generic Injectables Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Generic Injectables Players by Revenue
6.1.1 Global Top Generic Injectables Players by Revenue (2018-2023)
6.1.2 Global Generic Injectables Revenue Market Share by Players (2018-2023)
6.2 Global Generic Injectables Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Generic Injectables Head office and Area Served
6.4 Global Generic Injectables Players, Product Type & Application
6.5 Global Generic Injectables Players, Date of Enter into This Industry
6.6 Global Generic Injectables Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Generic Injectables Market Size (2018-2029)
7.2 North America Generic Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Generic Injectables Market Size by Country (2018-2023)
7.4 North America Generic Injectables Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Generic Injectables Market Size (2018-2029)
8.2 Europe Generic Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Generic Injectables Market Size by Country (2018-2023)
8.4 Europe Generic Injectables Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Generic Injectables Market Size (2018-2029)
9.2 Asia-Pacific Generic Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Generic Injectables Market Size by Country (2018-2023)
9.4 Asia-Pacific Generic Injectables Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Generic Injectables Market Size (2018-2029)
10.2 Latin America Generic Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Generic Injectables Market Size by Country (2018-2023)
10.4 Latin America Generic Injectables Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Generic Injectables Market Size (2018-2029)
11.2 Middle East & Africa Generic Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Generic Injectables Market Size by Country (2018-2023)
11.4 Middle East & Africa Generic Injectables Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Hospira (Pfizer Inc.)
11.1.1 Hospira (Pfizer Inc.) Company Detail
11.1.2 Hospira (Pfizer Inc.) Business Overview
11.1.3 Hospira (Pfizer Inc.) Generic Injectables Introduction
11.1.4 Hospira (Pfizer Inc.) Revenue in Generic Injectables Business (2017-2022)
11.1.5 Hospira (Pfizer Inc.) Recent Development
11.2 Fresenius Kabi
11.2.1 Fresenius Kabi Company Detail
11.2.2 Fresenius Kabi Business Overview
11.2.3 Fresenius Kabi Generic Injectables Introduction
11.2.4 Fresenius Kabi Revenue in Generic Injectables Business (2017-2022)
11.2.5 Fresenius Kabi Recent Development
11.3 Sandoz (Novartis)
11.3.1 Sandoz (Novartis) Company Detail
11.3.2 Sandoz (Novartis) Business Overview
11.3.3 Sandoz (Novartis) Generic Injectables Introduction
11.3.4 Sandoz (Novartis) Revenue in Generic Injectables Business (2017-2022)
11.3.5 Sandoz (Novartis) Recent Development
11.4 Hikma Pharmaceuticals PLC
11.4.1 Hikma Pharmaceuticals PLC Company Detail
11.4.2 Hikma Pharmaceuticals PLC Business Overview
11.4.3 Hikma Pharmaceuticals PLC Generic Injectables Introduction
11.4.4 Hikma Pharmaceuticals PLC Revenue in Generic Injectables Business (2017-2022)
11.4.5 Hikma Pharmaceuticals PLC Recent Development
11.5 Dr. Reddy’s Laboratories Ltd
11.5.1 Dr. Reddy’s Laboratories Ltd Company Detail
11.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
11.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Introduction
11.5.4 Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectables Business (2017-2022)
11.5.5 Dr. Reddy’s Laboratories Ltd Recent Development
11.6 Grifols
11.6.1 Grifols Company Detail
11.6.2 Grifols Business Overview
11.6.3 Grifols Generic Injectables Introduction
11.6.4 Grifols Revenue in Generic Injectables Business (2017-2022)
11.6.5 Grifols Recent Development
11.7 Nichi-Iko Group (Sagent)
11.7.1 Nichi-Iko Group (Sagent) Company Detail
11.7.2 Nichi-Iko Group (Sagent) Business Overview
11.7.3 Nichi-Iko Group (Sagent) Generic Injectables Introduction
11.7.4 Nichi-Iko Group (Sagent) Revenue in Generic Injectables Business (2017-2022)
11.7.5 Nichi-Iko Group (Sagent) Recent Development
11.8 Teva Pharmaceutical
11.8.1 Teva Pharmaceutical Company Detail
11.8.2 Teva Pharmaceutical Business Overview
11.8.3 Teva Pharmaceutical Generic Injectables Introduction
11.8.4 Teva Pharmaceutical Revenue in Generic Injectables Business (2017-2022)
11.8.5 Teva Pharmaceutical Recent Development
11.9 Auromedics
11.9.1 Auromedics Company Detail
11.9.2 Auromedics Business Overview
11.9.3 Auromedics Generic Injectables Introduction
11.9.4 Auromedics Revenue in Generic Injectables Business (2017-2022)
11.9.5 Auromedics Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Generic Injectables Introduction
11.10.4 Sanofi Revenue in Generic Injectables Business (2017-2022)
11.10.5 Sanofi Recent Development
11.11 Gland Pharma
11.11.1 Gland Pharma Company Detail
11.11.2 Gland Pharma Business Overview
11.11.3 Gland Pharma Generic Injectables Introduction
11.11.4 Gland Pharma Revenue in Generic Injectables Business (2017-2022)
11.11.5 Gland Pharma Recent Development
11.12 Endo International PLC
11.12.1 Endo International PLC Company Detail
11.12.2 Endo International PLC Business Overview
11.12.3 Endo International PLC Generic Injectables Introduction
11.12.4 Endo International PLC Revenue in Generic Injectables Business (2017-2022)
11.12.5 Endo International PLC Recent Development
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings